Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells (Sheba Medical Center)
- Development stage
- Unknown
- Lead developer
- Sheba Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy developed and manufactured in-house at Sheba Medical Center. While CD19 is traditionally a B-cell marker, it is aberrantly expressed in approximately 50-80% of acute myeloid leukemia (AML) patients with the t(8;21) translocation. The therapy involves genetically modifying a patient's own T-cells to express a CAR that targets and eliminates CD19-positive leukemic blasts. Produced as a point-of-care biologic, it features a rapid manufacturing turnaround of approximately 10 days. Clinical evaluation is currently focused on patients with relapsed or refractory AML who exhibit both the t(8;21) genetic abnormality and CD19 expression.
- Other names
- CD19 CAR-TCD-19 CAR-TCD 19 CAR-TCAR-T CD19anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cells (Sheba Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells (Sheba Medical Center).